These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24145087)

  • 1. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
    Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Detroja J; Patel K; Gandhi T; Patel K; Bahekar R; Jain M
    Pharmacol Rep; 2013; 65(4):927-36. PubMed ID: 24145087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
    Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
    J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats.
    Barakat GM; Moustafa ME; Bikhazi AB
    Biochem Genet; 2012 Dec; 50(11-12):922-35. PubMed ID: 22983684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
    Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
    Pharmacol Rep; 2012; 64(1):140-9. PubMed ID: 22580530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
    Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
    J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats.
    Barakat G; Moustafa ME; Khalifeh I; Hodroj MH; Bikhazi A; Rizk S
    J Physiol Biochem; 2016 Aug; 73(3):387-394. PubMed ID: 28589533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
    Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Patel V; Patel K; Bahekar R; Jain M
    Eur J Pharmacol; 2013 Aug; 714(1-3):188-92. PubMed ID: 23810686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.
    Himeno T; Kamiya H; Naruse K; Harada N; Ozaki N; Seino Y; Shibata T; Kondo M; Kato J; Okawa T; Fukami A; Hamada Y; Inagaki N; Seino Y; Drucker DJ; Oiso Y; Nakamura J
    Diabetes; 2011 Sep; 60(9):2397-406. PubMed ID: 21810596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
    Zheng YC
    Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.
    Wu H; Sui C; Xu H; Xia F; Zhai H; Zhang H; Weng P; Han B; Du S; Lu Y
    J Diabetes Res; 2014; 2014():524517. PubMed ID: 25580440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
    Ding X; Saxena NK; Lin S; Gupta NA; Anania FA
    Hepatology; 2006 Jan; 43(1):173-81. PubMed ID: 16374859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Kataoka HU; Takatsuka T; Miyamoto S; Sasaki M; Kajitani N; Nishishita S; Sarai K; Hirota D; Sato C; Ogawa D; Makino H
    Diabetologia; 2011 Apr; 54(4):965-78. PubMed ID: 21253697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas.
    Gezginci-Oktayoglu S; Bolkent S
    Biochem Cell Biol; 2009 Aug; 87(4):641-51. PubMed ID: 19767827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
    Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
    Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats.
    Kwon DY; Kim YS; Ahn IS; Kim DS; Kang S; Hong SM; Park S
    J Pharmacol Sci; 2009 Dec; 111(4):361-71. PubMed ID: 20019445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.